Intellectual Property - October 9, 2017
US patent approval for Cantargia
Cantargia announces that the United States Patent and Trademark Office has granted the company’s patent application directed to the product candidate CAN04. The antibody CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that USPTO issued in June 2017. The patent gives […]
Intellectual Property - September 25, 2017
Targovax granted US patent
Targovax announces that the US Patent and Trademark Office has granted US Patent no 9,757,439, which protects Targovax’ mutant-RAS specific neoantigen vaccines, TG01 and TG02, for the treatment of cancer in combination with anti-metabolite chemotherapy. “We are delighted that this US patent has been granted, further strengthening Targovax’ intellectual property portfolio covering the very important […]
Intellectual Property - September 13, 2017
Index Pharmaceuticals granted patent in Japan
The company announces that a new method of use patent for the drug candidate cobitolimod has been granted by the Japan Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy. […]
Intellectual Property - September 4, 2017
Patent granted for Moberg Pharma’s BUPI
Moberg Pharma announces that the Canadian Patent Office has issued Patent No. 2 860 373 which protects BUPI, currently in development for pain due to oral mucositis. The Canadian patent covers the use of a lozenge comprising a local anesthetic, e.g. bupivacaine, in a number of different indication, including treatment of pain due to oral […]
Global report - September 4, 2017
Pfizer’s patent criticized
The pharma giant was recently granted a patent on their vaccine for pneumonia in India, which has been highly questioned by for example Medecins sans Frontiers (MSF). The patent approval means that other pharma companies are not allowed to manufacture cheaper versions of the vaccine and this is a major backlash in the fight for […]
Biotech Business - September 1, 2017
New patent approval for Cantargia
Cantargia announces that the European Patent Office has granted the company’s patent application on the product candidate CAN04. CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that EPO issued in April 2017. The patent application with number 15714603.6 which was granted […]
